Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(1012)
•••
Comment by investclubon Dec 11, 2019 1:52pm
148 Views
Post# 30444633

RE:RE:RE:RE:Mackie Research comments on Theralase Technologies Inc.

RE:RE:RE:RE:Mackie Research comments on Theralase Technologies Inc.Even more fun Eoganacht will be how Theralase's competition will look in 1 year per  share price & outstanding shares  ...  hold onto that thought! 

Eoganacht wrote

True. Just for fun - here is the current share price and outstanding share count of our "competitors".

  Share Price  Shares Outstanding
Endo International PLC 4.46 USD 226,780,000
Cold Genesys privately owned  
Sesen 1.11 USD 104,680,000
Prometic Life Sciences 13.60 CAD 23,000,000
Theralase  .29 CAD 313,010,080

blackjack0 wrote: Whilst the chart shows Tld 1433 in a very positive light, it is actually way better like 100%  at both 3 and 6 month . Under phase two the patient that knocks them back to 66% would not have been included in the later tests




Bullboard Posts
Dealroom for high-potential pre-IPO opportunities